A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis

Table 5 Positive percentages of PPAR-γ and NF-κB in TG and CG

	TG (n = 21)		CG (n = 21)
	Initial point	Final point	Initial point	Final point
PPAR-γa (%)	26.2	47.76	24.9	39.24
	(22.98-29.49)	(43.42-50.09)	(21.49-28.32)	(35.81-42.67)
NF-κBc (%)	58.09	21.19	58	27
	(54.51-61.68)	(19.13-23.25)	(53.21-61.02)	(21.08-32.92)

^aP < 0.05, initial point to final point of TG vs CG;

^cP < 0.05, initial point to final point of TG vs CG.